mat2a inhibitor 1

MAT2A inhibitor 1 is an inhibitor of methionine adenosyltransferase 2A (MATA2) (IC50 < l00 nM).

FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. It can effectively compete with S-adenosylmethionine for MAT2A binding and has anticancer effects.

MAT2A ligand 1 is a MAT2A inhibitor (IC50=29.5 nM) that acts as a PET tracer capable of crossing the blood-brain barrier. It is utilized for non-invasive imaging of tumors expressing MAT2A, exhibiting rapid tumor uptake equilibrium, high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable in research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer.

MAT2A inhibitor 3 is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 value below 200 nM. MAT2A inhibitor 3 is utilized in cancer-related investigations and is relevant for studies involving methionine metabolism, S-adenosylmethionine biosynthesis, and metabolic regulation in tumor-associated cellular systems.

MAT2A-IN-4 can be used for the cancer research that is an inhibitor of methionine adenosyltransferase 2A (MAT2A)[1].

MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1].

MAT2A-IN-7, a potent inhibitor of the enzyme MAT2A, demonstrates efficacy in targeting the abnormally elevated expression of MAT2A observed in gastric, colon, liver, and pancreatic cancers. Furthermore, MAT2A-IN-7 effectively reduces the proliferative activity specifically in MTAP-deficient cancer cells, thus highlighting its potential for cancer research applications [1].

MAT2A-IN-1 is a potent inhibitor of MAT2A, displaying proliferative activity in MTAP-deficient cancer cells. MAT2A is highly expressed in several tumours, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-1 shows significant potential for cancer research.

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an IC50 value of 6.8 nM [1].

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP -/- cell line [1].

MAT2A-IN-13 is a potent, orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile, demonstrating in vivo efficacy in an HCT-116 MTAP-deleted xenograft model and potential use in MTAP-deleted tumors treatment research [1].